TD Cowen has lowered its price target for Chewy Inc. (NYSE:CHWY) to $32 from $34, while maintaining a Buy rating, citing a challenging outlook for the pet market. Despite Chewy's Q2 fiscal 2026 revenue slightly exceeding expectations and EBITDA beating estimates due to one-time items, Q3 EBITDA guidance was weaker than anticipated. This led to an 11% fall in Chewy's shares, trading significantly below InvestingPro's Fair Value analysis, and comes amidst mixed analyst reactions including downgrades from Evercore ISI and RBC Capital, though Needham and Citizens maintained positive ratings.

Incyte Corporation discussed its pipeline advancements and post-Jakafi strategy at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company is focusing on growing its core business to $3-4 billion with multiple launches and developing five cornerstone assets in Phase III trials to support recovery after Jakafi's exclusivity ends post-2029. Key initiatives include expanding its KRAS G12D inhibitor program, advancing its CALR antibody for myeloproliferative neoplasms, and developing a TGFβR2xPD-1 bispecific for colorectal cancer, aiming for top-quartile growth and strategic, selective business development.

This article from Investing.com reports the filing of a Form 8K by T3 Defense Inc. on September 10. The content of the 8K filing is not detailed within the provided text, but it signals a significant event for the company that warrants public disclosure.

IBM successfully defended against a former employee's claims of sex and pregnancy discrimination after she was transferred to a new position following maternity leave. The US District Court for the Northern District of Texas ruled that De’Aundria Lee, who resigned in 2025, failed to prove her reassignment was a demotion rather than a lateral transfer. IBM stated the transfer was part of a larger "redeployment" initiative impacting approximately 100 employees to align with business needs.

Teekay Tankers Ltd (TNK) stock reached a new 52-week high of $94.56, reflecting an 81.16% increase over the past year. Despite this surge, InvestingPro data suggests the company is undervalued with a Fair Value of $107.68, supported by a low P/E ratio and strong return on assets. The company recently reported record-breaking Q2 results with adjusted net income of $194 million and robust revenue of $379.5 million, highlighting strong performance in the tanker market.

AT&T (T) stock is seeking a supportive bottom after moving lower in intraday trading. The stock remains in a short-term bullish corrective trend, supported by its 50-day Simple Moving Average, and momentum indicators suggest a potential bullish divergence. The outlook for AT&T is bullish, provided support at $24.20 holds, with an expected retest of the $26.45 resistance level.

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives, including CEO Jeff Simmons and CFO Bob VanHimbergen, will participate in a fireside chat. A live audio webcast and replay will be available on Elanco's investor website.

DuPont, Chemours, and Corteva have reached a settlement with North Carolina regarding PFAS and other emissions from the Fayetteville Works facility. Qnity Electronics, Inc. disclosed an indemnification liability of $43 million, representing its 44% share of DuPont's after-tax liability from the settlement. The agreement outlines how current and future litigation settlements will be counted against a 2021 Memorandum of Understanding limit at net present value.

Johnson & Johnson has secured CE Marking for its Acuvue Oasys MAX 2-Week contact lens, a reusable lens featuring OptiBlue Light Filter and TearStable Technology. This lens is set to launch in select European markets in late 2026 and expands the existing Acuvue Oasys MAX portfolio. It has not yet received FDA approval for sale in the U.S.

Cooper Companies (NASDAQ: COO) reported mixed Q3 financial results, beating earnings estimates but missing sales forecasts, and subsequently lowered its FY26 guidance. Following this announcement, several analysts downgraded the stock and reduced their price targets, leading to a significant dip in Cooper Companies' shares during pre-market trading. The company's CEO noted that while earnings exceeded expectations and fertility growth was solid, reduced U.S. channel inventory at CooperVision negatively impacted results.